nitrosyl


Also found in: Dictionary, Wikipedia.

ni·tro·syl

(nī'trō-sil),
A univalent radical or atom group, -N=O, forming the nitroso compounds.

ni·tro·syl

(nī'trō-sil)
A univalent radical or atom group, -N=O, forming the nitroso compounds.
Mentioned in ?
References in periodicals archive ?
Synthesis, charecterization and nitric oxide release profile of nitrosyl cobalamin : a potential chemotherapeutic agent.
Another theory purports that a complex series of steps occurs in the pyrolyzer leading to the formation of the nitrosyl radical, causing the response.
com), a privately held, advanced development-stage technology company, announced that a study of GeNO's NITROSYL Delivery System during Right Heart Catheterization (RHC) in subjects being evaluated for Orthotopic Heart Transplantation (OHT) and Left Ventricular Assist Device (LVAD) implantation was presented at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting in Prague, Czech Republic.
GeNO's NITROSYL Delivery System was used to deliver NO at a concentration of 80 PPM for 15 minutes by nasal cannula with air or O2.
Both classes of nitrosyl compounds originate with the corresponding hexacarbonyls as summarized in equations 1 to 4, 1,2 :
The halo nitrosyl products of reactions 3 and 4 being the synthetic precursors to the species of interest (vide infra).
Luke's Medical Center in Milwaukee is scheduled to present the abstract, " An Open Label Non-Randomized Pilot Study To Evaluate the Safety of the GeNO Nitrosyl Delivery System in Patients Being Evaluated for Heart Transplantation.
The primary aim of the study is to evaluate the safety, tolerability and device performance of the GeNO NITROSYL Delivery System during RHC.
In December 2010, GeNO initiated its first clinical study, a 10 patient Pilot Study to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide via the GeNO Nitrosyl delivery system.
com) a privately held, advanced development-stage technology company announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the GeNO NITROsyl (Inhaled Nitric Oxide) System for the treatment of pulmonary hypertension in patients with pulmonary arterial hypertension (PAH) and in patients with pulmonary hypertension secondary to idiopathic pulmonary fibrosis (PH-IPF).
Following the dose escalation study, it is planned to study these two populations for 12 weeks in a multicenter, randomized, double-blind, placebo-controlled study using the new GeNO ambulatory NITROsyl platform, which will allow for 24-7 inhalation of nitric oxide by means of a nasal cannula.
The initial indication to be studied for nitric oxide delivered via the GeNO Nitrosyl delivery system is as a diagnostic agent for administration as an adjunct to right heart catheterization in patients with Pulmonary Arterial Hypertension (WHO Group 1) to add information to improve clinical decision making.